MLYS Mineralys Therapeutics, Inc.

Price Chart

Executive Summary

Mineralys Therapeutics entered into a $200M one-time cash payment to Tanabe Pharma to buy out all future royalty obligations on lorundrostat, converting the license to a perpetual, royalty-free, worldwide grant. Simultaneously, the company secured a $500M senior secured term loan facility from Pharmakon Advisors, with an initial $100M draw and additional tranches tied to FDA approval and sales milestones. The combination eliminates a major cash-flow liability (royalties) but adds significant secured debt and covenants, creating a mixed risk/reward profile ahead of the lorundrostat NDA decision.

Actionable Insight

Key Facts

• One-time cash payment of $200.0 million to Tanabe Pharma to terminate future royalty payments on lorundrostat
• License converted to exclusive, worldwide, royalty-free, perpetual, and irrevocable; Tanabe will assign all IP rights
• Remaining milestone obligations to Tanabe: up to $255.0M on first commercial sale and annual sales targets, plus up to $10.0M for a second indication
• New commercial milestones of up to $100.0M added; these become immediately payable upon a change of control involving U.S. commercialization rights
• Entered into a $500.0M senior secured term loan facility with Pharmakon Advisors (BioPharma Credit funds)
• Tranche A: $100.0M drawn on closing; Tranche B: $150.0M (must be drawn by April 30, 2027, subject to FDA NDA approval); Tranche C: $150.0M (optional until Dec 2028); Tranche D: $100.0M (optional until June 2029)
• Interest rate: 3-month SOFR (3.25% floor) + 5.50%, payable quarterly; 2.00% funding fee on each tranche
• Loan secured by substantially all assets including IP; financial covenants include minimum liquidity pre-NDA approval and minimum trailing 12-month net product revenue starting Q1 2029
• If Tranche B approval condition not met by Sept 30, 2027, all term loans must be repaid in four equal installments starting that date
• Loan restricts dividends, share repurchases, additional indebtedness, asset sales, and change of control unless all amounts are paid in full

Financial Impact

Immediate cash outflow of $200M to Tanabe; up to $500M in new debt with $100M drawn at close; remaining milestones of up to $365M in aggregate; elimination of all future royalty payments on lorundrostat sales

Risk Factors

• FDA non-approval or delay of lorundrostat NDA would trigger mandatory loan repayment starting Sept 2027, creating liquidity crisis
• Total debt of up to $500M secured by all assets including IP — default could mean loss of core asset
• Remaining milestone payments of up to $365M to Tanabe add contingent liability
• Covenants restrict financial flexibility: no dividends, share buybacks, or additional debt without consent
• Change-of-control provision on new milestones could complicate or deter acquisition offers

Market Snapshot

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

US Market Status